William Grossman
CIK 1730229 · Interim Chief Medical Officer · last filed 2026-06-17
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$669.2K
Companies
4
Total Filings
21
Lifetime Open-Market Net
-$432.2K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ENGNW | Interim Chief Medical Officer | — | $0.36 | — | $0 | 2 | 2026-06-17 |
| Day One Biopharmaceuticals, Inc. (DAWN) Delisted | Director | — | $21.53 | — | $0 | 5 | 2026-04-23 |
| RCUS | Chief Medical Officer | 24,741 | $27.05 | $669.2K | -$432.2K | 11 | 2021-06-21 |
| BELLICUM PHARMACEUTICALS, INC (BLCM) Delisted | Sr. VP, Chief Medical Officer | 2,687 | $0.07 | $201 | $0 | 3 | 2019-02-07 |
Recent Filings · Page 2 of 3
21 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-01-20 | RCUS | Grant (A) | +18,750 | $0 | EDGAR |
| 2020-12-18 | RCUS | Sell (S) | −2,117 | -$66.4K | EDGAR |
| 2020-10-05 | RCUS | Grant (A) | +100,000 | $0 | EDGAR |
| 2020-08-04 | RCUS | Buy (P) | +200 | $3.9K | EDGAR |
| 2020-06-08 | RCUS | Grant (A) | +55,000 | $0 | EDGAR |
| 2020-01-22 | RCUS | Grant (A) | — | $0 | EDGAR |
| 2019-10-15 | RCUS | Buy (P) | +400 | $3.2K | EDGAR |
| 2019-05-01 | RCUS | Grant (A) | — | $0 | EDGAR |
| 2019-02-07 | BELLICUM PHARMACEUTICALS, INC (BLCM) Delisted | Tax (F) | −3,126 | -$10.9K | EDGAR |
| 2019-02-05 | BELLICUM PHARMACEUTICALS, INC (BLCM) Delisted | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.